News
AXDX
1.040
+4.76%
0.047
CLVS, TCOM and GTE among pre market gainers
Axsome Therapeutics (AXSM) +50%as FDA issues proposed labeling for depression drug. Agile Therapeutics (AGRX) +42%. Nutex Health (NUTX) +14%announces that it has been selected to join both the RUSSELL 2000® AND
Seekingalpha · 4d ago
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
Benzinga · 4d ago
Accelerate Diagnostics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, Accelerate Diagnostics's (NASDAQ:AXDX) reported sales totaled $2.96 million. Despite a 37.79% increase in earnings, the company posted a loss of $14.19 million.
Benzinga · 06/21 13:51
Insiders may be rethinking their US$11m Accelerate Diagnostics, Inc. (NASDAQ:AXDX) investment now that the company has lost US$6.4m in value
Insiders who bought US$11m worth of Accelerate Diagnostics, Inc.'s ( NASDAQ:AXDX ) stock at an average buy price of...
Simply Wall St. · 06/13 10:55
MVST, OMEX and REKR among mid-day movers
Gainers: Heart Core Enterprises (HTCR) +151%. MINISO Group Holding (MNSO) +33%. Imperial Petroleum (IMPP) +33%. Cyren (CYRN) +33%. One Connect Financial Technology (OCFT) +27%. SQL Technologies (SKYX) +27%. Rekor Systems
Seekingalpha · 06/08 16:56
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback.
Benzinga · 06/08 16:29
DBV, Rubius top healthcare gainers; Rigel, Cosmos lead losers' pack
Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) -9%. Omeros (OMER...
Seekingalpha · 06/08 14:02
China Petroleum & Chemical, Credit Suisse Group, The Scotts Miracle-Gro among premarket losers' pack
Rigel Pharmaceuticals (RIGL) -49% after reports top-line results from FORWARD Phase 3 trial of Fostamatinib in patients with warm autoimmune hemolytic anemia. AeroClean Technologies (AERC) -17%. The Scotts Miracle-Gro SMG -13% as it cuts
Seekingalpha · 06/08 12:38
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Benzinga · 06/06 09:31
Accelerate Diagnostics to Participate in 42nd Annual William Blair Growth Stock Conference on June 7, 2022
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, will present at the 42nd Annual William Blair Growth Stock Conference on Thursday, June 7, 2022, at 10:00 AM Central Time.
PR Newswire · 05/23 13:30
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Tops Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/16 22:15
Recap: Accelerate Diagnostics Q1 Earnings
Accelerate Diagnostics (NASDAQ:AXDX) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Benzinga · 05/16 21:43
Accelerate Diagnostics Q1 EPS $(0.25) Beats $(0.30) Estimate, Sales $2.96M Beat $2.95M Estimate
Accelerate Diagnostics (NASDAQ:AXDX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 16.67 percent. This is a 39.02 percent increase over losses of $(0.41) per share
Benzinga · 05/16 20:44
Accelerate Diagnostics GAAP EPS of -$0.21 beats by $0.09, revenue of $2.96M beats by $0.01M
Accelerate Diagnostics press release (NASDAQ:AXDX): Q1 GAAP EPS of -$0.21 beats by $0.09. Revenue of $2.96M (+18.4% Y/Y) beats by $0.01M.
Seekingalpha · 05/16 20:16
Stocks That Hit 52-Week Lows On Monday
  On Monday, 198 companies reached new 52-week lows.
Benzinga · 05/16 17:59
-- Earnings Flash (AXDX) ACCELERATE DIAGNOSTICS Reports Q1 Revenue $3M
MT Newswires · 05/16 16:22
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Benzinga · 05/16 13:39
BRIEF-Accelerate Diagnostics Announces Commercialization Of Its Accelerate Arc System Having Completed IVD Registration With FDA
reuters.com · 05/16 12:07
Accelerate Diagnostics announces commercialization of its Accelerate Arc™ system having completed IVD registration with FDA
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, today announced commercialization of its new Accelerate Arc Module and BC kit.
PR Newswire · 05/16 12:06
Earnings Scheduled For May 16, 2022
  Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Benzinga · 05/16 09:18
More
Webull provides a variety of real-time AXDX stock news. You can receive the latest news about Accelerate Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AXDX
Accelerate Diagnostics, Inc. is an vitro diagnostics company engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.